Editorial: Innate lymphoid cells in cancer: volume II
-
By
-
Nicolas Jacquelot
-
Emilie Narni-Mancinelli
-
Alexander David Barrow
-
June 15, 2026
-
Clinical Scorecard: Editorial: The Role of Innate Lymphoid Cells in Cancer Research - Volume II
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | ILCs modulate cancer progression and therapeutic outcomes through interactions with the tumor microenvironment, as noted in the source. |
| Target Population | |
| Care Setting | |
Key Highlights
- ILCs include NK cells, ILC1, ILC2, ILC3, and LTi cells, functioning independently of antigen-specific receptors.
- ILCs can either restrain or promote tumor growth depending on tumor type and stage, as discussed in the source.
- A 25-parameter spectral flow cytometry panel has been developed for high-resolution discrimination of ILC subsets.
- ILT2 is identified as a key immune checkpoint in hepatocellular carcinoma, associated with impaired NK cell cytotoxicity.
- CD56bright NK cells may correlate with favorable prognosis in bladder tumors.
Guideline-Based Recommendations
Diagnosis
- Utilize advanced flow cytometry techniques for characterization of ILC populations in tumors.
Management
- Explore therapeutic strategies that manipulate ILC functions toward anti-tumor immunity, as suggested in the source.
Monitoring & Follow-up
- Assess the expression of immune checkpoints and cytokines in ILCs.
Risks
- Consider the potential for exacerbating inflammation or autoimmunity when targeting ILCs.
Patient & Prescribing Data
Cytokine-driven phenotypes of ILCs may contribute to tumor progression and response to immunotherapy, as indicated in the source.
Clinical Best Practices
- Integrate ILC biology into cancer immunotherapy development, as emphasized in the source.
- Monitor ILC subset dynamics in response to treatment.
Related Resources & Content
